'Pull every lever': Marks doubles down on urgency to improve gene therapy manufacturing
FDA’s biologics leader Peter Marks has a warning for gene therapy manufacturers and the healthcare payers that cover them: If they can’t streamline manufacturing in the next 10 years, gene therapies could become increasingly inaccessible to the patients that could rely on them.
Speaking on a panel at the Milken Institute Future of Health Summit on Monday, Marks highlighted the challenges facing gene therapy manufacturing and reiterated his call to drastically ramp up gene therapy development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.